Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Overdose Prevention Centers topic
No spam. Unsubscribe anytime.
Committee hears broad support and questions for overdose‑prevention center pilot (HB 8 45)
Summary
Delegates and witnesses described overdose prevention centers as a harm‑reduction approach that can reverse overdoses, reduce emergency calls, and connect people to care; sponsors sought pilot authority but faced questions about community impacts and evidence.
The committee heard extensive testimony on House Bill 8 45, which would authorize a pilot program to permit up to six local overdose prevention centers (OPCs) in non‑residential areas with high drug use. Supporters — including medical professionals, harm‑reduction advocates and people with lived experience — said OPCs provide supervised spaces where trained staff can reverse overdoses, reduce emergency calls, connect people to treatment, and reduce syringe litter.
Dr. Halia Melnick (presenting for the bill) described OPCs as monitored sites that do not supply drugs but instead allow people to use in the presence of staff trained to reverse overdoses. She and witnesses cited international evidence and examples from New York City, where staff at OPCs reported reversing more than 1,700 overdoses since 2021. Christine Obway (assistant commissioner, Baltimore City Health Department) and other public‑health witnesses described studies they said show reductions in hospitalizations, HIV and hepatitis C infections and ambulance runs in areas with supervised consumption sites.
People with lived experience and advocates told personal stories: volunteers described on‑site drug testing and rapid overdose response at music festivals, and family members described losing loved ones and urged legislative action. Harm‑reduction providers described services beyond overdose reversal — bathrooms, showers, laundry, referrals, and testing — that they said improve health and neighborhood conditions.
Committee members asked opponents’ concerns: whether OPCs “enable” drug use, whether nonprofits have the capacity to purchase and cancel debt (in a separate bill discussion that followed), and how OPCs would affect neighborhoods — including questions about congregating or lines outside sites. Witnesses said evidence shows OPCs do not increase crime and that most clients report they would otherwise use in public spaces; witnesses noted successful community education and demonstration projects to build support.
Opponents did not dominate the hearing; questions were mostly from members seeking operational details. Sponsors and advocates said they would continue public outreach and emphasized an incremental pilot limited to non‑residential locations. No committee action occurred at the hearing.
